Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Improving sexual health through partner notification: the LUSTRUM mixed-methods research Programme including RCT of accelerated partner therapy.
Estcourt CS, Mapp F, Woode Owusu M, Low N, Flowers P, Copas A, Roberts TE, Mercer CH, Saunders J, Nandwani R, Althaus CL, Stirrup O, Symonds M, Howarth AR, Johnson AM, Okeke Ogwulu C, Pothoulaki M, Vojt G, Wayal S, Brice S, Comer-Schwartz A, Tostevin A, Williams E, Lasoye S, McQueen J, Abdali Z, Cassell JA. Estcourt CS, et al. Among authors: tostevin a. Southampton (UK): National Institute for Health and Care Research; 2024 Mar. Southampton (UK): National Institute for Health and Care Research; 2024 Mar. PMID: 38530912 Free Books & Documents. Review.
Bone turnover change after randomized switch from tenofovir disoproxil to tenofovir alafenamide fumarate in men with HIV.
Moore AEB, Burns JE, Sally D, Milinkovic A, Krokos G, John J, Rookyard C, Borca A, Pool ERM, Tostevin A, Harman A, Dulnoan DS, Gilson R, Arenas-Pinto A, Cook GJR, Saunders J, Dunn D, Blake GM, Pett SL. Moore AEB, et al. Among authors: tostevin a. AIDS. 2024 Mar 15;38(4):521-529. doi: 10.1097/QAD.0000000000003811. Epub 2024 Feb 1. AIDS. 2024. PMID: 38061030 Free PMC article. Clinical Trial.
Rate of response to initial antiretroviral therapy according to level of pre-existing HIV-1 drug resistance detected by next-generation sequencing in the strategic timing of antiretroviral treatment (START) study.
Cozzi-Lepri A, Dunn D, Tostevin A, Marvig RL, Bennedbaek M, Sharma S, Kozal MJ, Gompels M, Pinto AN, Lundgren J, Baxter JD; INSIGHT START Study Group. Cozzi-Lepri A, et al. Among authors: tostevin a. HIV Med. 2024 Feb;25(2):212-222. doi: 10.1111/hiv.13556. Epub 2023 Sep 29. HIV Med. 2024. PMID: 37775947
Accelerated partner therapy contact tracing for people with chlamydia (LUSTRUM): a crossover cluster-randomised controlled trial.
Estcourt CS, Stirrup O, Copas A, Low N, Mapp F, Saunders J, Mercer CH, Flowers P, Roberts T, Howarth AR, Owusu MW, Symonds M, Nandwani R, Ogwulu C, Brice S, Johnson AM, Althaus CL, Williams E, Comer-Schwartz A, Tostevin A, Cassell JA. Estcourt CS, et al. Among authors: tostevin a. Lancet Public Health. 2022 Oct;7(10):e853-e865. doi: 10.1016/S2468-2667(22)00204-3. Lancet Public Health. 2022. PMID: 36182235 Free article. Clinical Trial.
Using machine learning and big data to explore the drug resistance landscape in HIV.
Blassel L, Tostevin A, Villabona-Arenas CJ, Peeters M, Hué S, Gascuel O; UK HIV Drug Resistance Database. Blassel L, et al. Among authors: tostevin a. PLoS Comput Biol. 2021 Aug 26;17(8):e1008873. doi: 10.1371/journal.pcbi.1008873. eCollection 2021 Aug. PLoS Comput Biol. 2021. PMID: 34437532 Free PMC article.
Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study.
Baxter JD, Dunn D, Tostevin A, Marvig RL, Bennedbaek M, Cozzi-Lepri A, Sharma S, Kozal MJ, Gompels M, Pinto AN, Lundgren J; INSIGHT START Study Group. Baxter JD, et al. Among authors: tostevin a. HIV Med. 2021 May;22(5):360-371. doi: 10.1111/hiv.13038. Epub 2020 Dec 25. HIV Med. 2021. PMID: 33369017 Free PMC article.
Accelerated partner therapy (APT) partner notification for people with Chlamydia trachomatis: protocol for the Limiting Undetected Sexually Transmitted infections to RedUce Morbidity (LUSTRUM) APT cross-over cluster randomised controlled trial.
Estcourt CS, Howarth AR, Copas A, Low N, Mapp F, Woode Owusu M, Flowers P, Roberts T, Mercer CH, Wayal S, Symonds M, Nandwani R, Saunders J, Johnson AM, Pothoulaki M, Althaus C, Pickering K, McKinnon T, Brice S, Comer A, Tostevin A, Ogwulu CD, Vojt G, Cassell JA. Estcourt CS, et al. Among authors: tostevin a. BMJ Open. 2020 Mar 29;10(3):e034806. doi: 10.1136/bmjopen-2019-034806. BMJ Open. 2020. PMID: 32229523 Free PMC article.
Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation.
Stirrup OT, Asboe D, Pozniak A, Sabin CA, Gilson R, Mackie NE, Tostevin A, Hill T, Dunn DT; UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort. Stirrup OT, et al. Among authors: tostevin a. HIV Med. 2020 May;21(5):309-321. doi: 10.1111/hiv.12829. Epub 2020 Jan 11. HIV Med. 2020. PMID: 31927793 Free PMC article.
Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV.
Stirrup OT, Sabin CA, Phillips AN, Williams I, Churchill D, Tostevin A, Hill T, Dunn DT; UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort. Stirrup OT, et al. Among authors: tostevin a. J Virus Erad. 2019 Nov 4;5(4):204-211. J Virus Erad. 2019. PMID: 31754443 Free PMC article.
44 results